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difﬁcult. In traditional clinical trials challenges to completeness
and accuracy of cost data and protocol-induced bias may reduce
generalizability of results. “Real-world” trials are potentially
useful but few have been conducted. With readily available
claims data, the practical approach is to use cost-to-charge ratio
to estimate the dollar value of consumed resources. This paper
examines the characteristics and cost-to-charge ratio for CABG
patients by hospital and department over time. METHODS:
Premier data for 17,000 CABG patients from 187 US hospitals
between 2002 and 2004 were used. Hospital cost-to-charge
ratios were estimated with patient level total cost and charges at
discharge and within each department. Cost-to-charge ratio by
hospital type and location were assessed. RESULTS: Cost-
to-charge ratios were not associated with hospital bed size
although from 2002 to 2004, the ratios decreased ranging from
2% to 14% percent indicating improved efﬁciency for all hos-
pitals. The cost-to-charge ratio disparity between teaching and
non-teaching hospitals is shrinking over time (0.43 vs. 0.40 and
0.39 vs. 0.38 at year 2002 and 2004, respectively). The cost-to-
charge ratio gap between urban and rural hospitals remains over
time (0.48 vs. 0.40 at year 2002, 0.46 vs. 0.37 at year 2004).
With regard to departmental cost-to-charge ratio, they differ
greatly by hospital department and vary across hospitals. Except
for anesthesia, for teaching hospitals departmental cost-to-
charge ratios declined on average by 14% (4% to 28%) from
2002 to 2004. For non-teaching hospitals, changes over time
were mixed. For urban hospitals, departmental cost-to-charge
ratios had declining patterns similar to that of teaching hospi-
tals. CONCLUSIONS: Cost-to-charge ratio for CABG patients
varies by hospital type and these differences declined over time.
Appropriate cost-to-charge ratios must be used in order to
produce valid cost estimates.
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OBJECTIVES: First, estimate the prevalence of diet/nutrition
(DN) and exercise counseling (EC) in patients with dyslipidemia
during ambulatory care visits in the United States. Secondly,
compare the likelihood of receiving DN or EC across various
patient and physician characteristics. METHODS: The National
Ambulatory Medical Care Survey (NAMCS) data for 2000 and
2001 were merged to obtain cross-sectional nationwide estimates
of DN and EC. Dyslipidemia patients were identiﬁed by ICD-9
codes (272.XX). Sampling weights were provided by the
NAMCS and logistic regressions were used. RESULTS: A total
of 29.6 million (2-year average) visits in the U.S. had a diagno-
sis of dyslipidemia (n = 1620). Provision of DN was greater than
EC (37% and 25%, respectively). Men were statistically signiﬁ-
cantly more likely to receive DN and EC than women, after
adjusting for race and age (OR = 1.2 and 1.3, respectively). After
adjusting for race and gender, subjects aged 50–64 years were
more likely to receive DN than any other age group and subjects
aged 30–49 were more likely to receive EC than any other age
group. Compared to whites, blacks were 30% and 10% more
likely to receive DN and EC, respectively, after adjusting for age
and gender. It was found that self-paying subjects were more
likely to receive EC (OR = 1.2, p = 0.003) but less likely to
receive DN (OR = 0.72, p = 0.0002) than subjects with private
insurance. Physicians located in the West provided greater pro-
visions of DN and EC when compared to physicians located in
other parts of the United States (OR = 2.2 and 1.5, respectively).
Compared to internists or cardiologists, family medicine physi-
cians provided more DN and EC (p < 0.0001). CONCLUSION:
Over two years, provisions of DN and EC were relatively low.
More efforts in providing these preventative measures are 
warranted.
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OBJECTIVES: To predict high-risk patients with cardiovascular
disease (CVD) over a 1, 2, and 3 year time period. Good pre-
diction models will enable health care providers to target high
risk patients who would most beneﬁt from intervention pro-
grams designed to improve CVD patient outcomes. METHODS:
Using classiﬁcation and regression tree (C&RT) analysis from
AnswerTree (SPSS 3.0), risk models were developed using 
California Medicaid (Medi-Cal) medical and pharmaceutical
claims data for 62,154 patients with a diagnosis of CVD. Vari-
ables deﬁned for the 6-month pre-period were used to predict
year 1, year 2, and year 3 total costs. To determine the predic-
tive ability of the model, we designated high cost patients as
those with total costs of greater than $10,000, and low cost
patients as those with less than $10,000. RESULTS: Outpatient
cost (of approximately $3600, >1 SD above the median) in the
six months prior to diagnosis was the most common split. Other
contributing factors were patient comorbidities, including Other
Neurological Disorders (p < 0.01), Deﬁciency Anemias (p <
0.01), and Hypertension (p < 0.01). Results for years 2 and 3
were similar to year 1 ﬁndings. With further examination of the
data, we found that the small group of high cost patients at Year
1 continue to be high cost patients in the subsequent years,
although nearly 14.5% drop out at year 2 and 14.5% dropout
from year 2 to year 3. 35% of the sample was correctly grouped
into the high-cost branch, while 98% of the low-cost subjects
were correctly grouped into the low-cost branch. CONCLU-
SIONS: C&RT is a useful method in predicting high risk
patients. As demonstrated in this sample, patients incurring high
costs were signaled through outpatient utilization, and were cor-
rectly identiﬁed with a sensitivity of 35% and a speciﬁcity of
98%.
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OBJECTIVE: The Expected Value of Perfect Information (EVPI)
is becoming an increasing valuable tool to assist healthcare deci-
sion makers with their choices of new healthcare technologies.
Although the use of EVPI in healthcare decision making is on
the rise the study of its properties has received little attention.
This study will evaluate the properties of the EVPI in the context
of a currently published model for a cholesterol lowering
therapy. METHODS: The properties of the EVPI were studied
using a Markov chain model that evaluated the cost-effective-
ness of ezetimibe co-administration with statin therapy vs statin
titration (Cook et al. 2004). Simulations of the model were run
for iterations of size 1000, 10,000 and 100,000. Baseline deci-
sions were evaluated for blocks of 1000 iterations and the
percent of correct optimal decisions as well as the mean and stan-
dard deviation for the net beneﬁts were tabulated within each
block. RESULTS: The estimated EVPI for 1000, 10,000 and
